The Clonmel manufacturing facility of global healthcare company Abbott Vascular has been awarded the Shingo Prize, a leading international award for operational
The award was presented by the Shingo Institute at the Jon M. Huntsman School of Business at Utah State University.
Abbott’s Clonmel facility achieved the award following a decade-long journey to achieve operational excellence.
The prize is awarded to organisations that demonstrate a culture where principles of operational excellence are deeply embedded into the thinking and behaviour of all leaders, managers and associates.
The accolade is recognised as a premier award for operational excellence and the standard is one of the most rigorous in the world. It is open to organisations across all industries and sectors internationally. Abbott’s manufacturing facility in Clonmel is the first organisation in Europe to achieve the standards required to receive the top Shingo Prize.
Due to the high bar set by the assessors for receiving the Shingo, there was no recipient of the top award worldwide last year and just two companies outside of Europe received the honour in 2012.
Abbott’s Clonmel facility is a centre of excellence in the manufacturing of medical devices used to treat people with vascular diseases, including heart disease, in more than 100 countries around the world.
By adopting the Shingo model, the team at Abbott was able to further develop and strengthen its long-term vision and strategy, discover the most effective ways to foster collaboration among employees, and identify opportunities to enhance the way the company manufactures medical devices. As a result, the Clonmel site has achieved significant increases in productivity while maintaining the highest standards in quality, as it brings innovative medical technologies to the market.
“Our journey to performance excellence has been a conscious and collaborative effort that has been ongoing since 2004,” said William Boxwell, Clonmel site director, Abbott.